Literature DB >> 25596079

Analysis of human innate immune responses to PRINT fabricated nanoparticles with cross validation using a humanized mouse model.

Gregory R Robbins1, Reid A Roberts1, Haitao Guo1, Kevin Reuter2, Tammy Shen3, Gregory D Sempowski4, Karen P McKinnon1, Lishan Su1, Joseph M DeSimone5, Jenny P-Y Ting6.   

Abstract

Ideal nanoparticle (NP)-based drug and vaccine delivery vectors should be free of inherent cytotoxic or immunostimulatory properties. Therefore, determining baseline immune responses to nanomaterials is of utmost importance when designing human therapeutics. We characterized the response of human immune cells to hydrogel NPs fabricated using Particle Replication in Non-wetting Templates (PRINT) technology. We found preferential NP uptake by primary CD14(+) monocytes, which was significantly reduced upon PEGylation of the NP surface. Multiplex cytokine analysis of NP treated primary human peripheral blood mononuclear cells suggests that PRINT based hydrogel NPs do not evoke significant inflammatory responses nor induce cytotoxicity or complement activation. We furthered these studies using an in vivo humanized mouse model and similarly found preferential NP uptake by human CD14(+) monocytes without systemic inflammatory cytokine responses. These studies suggest that PRINT hydrogel particles form a desirable platform for vaccine and drug delivery as they neither induce inflammation nor toxicity. From the clinical editor: The authors here fabricated hydrogel nanorods using the PRINT (Particle Replication In Nonwetting Templates) fabrication process. They tested the interaction of human immune cells with these particles and found no immunoreactivity. This finding would suggest that monodisperse PRINT particles of identical shape and size could serve a variety of clinical applications.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complement; Humanized mice; Monocytes; Nanoparticles; PEGylation; PRINT; Toxicity

Mesh:

Substances:

Year:  2015        PMID: 25596079      PMCID: PMC4385431          DOI: 10.1016/j.nano.2014.11.010

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  50 in total

Review 1.  Immunological properties of engineered nanomaterials.

Authors:  Marina A Dobrovolskaia; Scott E McNeil
Journal:  Nat Nanotechnol       Date:  2007-07-29       Impact factor: 39.213

Review 2.  Polymeric particles in vaccine delivery.

Authors:  Allison C Rice-Ficht; Angela M Arenas-Gamboa; Melissa M Kahl-McDonagh; Thomas A Ficht
Journal:  Curr Opin Microbiol       Date:  2010-01-14       Impact factor: 7.934

Review 3.  PEG conjugates in clinical development or use as anticancer agents: an overview.

Authors:  Gianfranco Pasut; Francesco M Veronese
Journal:  Adv Drug Deliv Rev       Date:  2009-08-09       Impact factor: 15.470

4.  Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials.

Authors:  Jason P Rolland; Benjamin W Maynor; Larken E Euliss; Ansley E Exner; Ginger M Denison; Joseph M DeSimone
Journal:  J Am Chem Soc       Date:  2005-07-20       Impact factor: 15.419

5.  Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals.

Authors:  Peter Scott; Hong Ma; Suganya Viriyakosol; Robert Terkeltaub; Ru Liu-Bryan
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

6.  HIV-1 infection and pathogenesis in a novel humanized mouse model.

Authors:  Liguo Zhang; Grigoriy I Kovalev; Lishan Su
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

7.  Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome.

Authors:  Fiona A Sharp; Darren Ruane; Benjamin Claass; Emma Creagh; James Harris; Padma Malyala; Manomohan Singh; Derek T O'Hagan; Virginie Pétrilli; Jurg Tschopp; Luke A J O'Neill; Ed C Lavelle
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-12       Impact factor: 11.205

8.  Double-stranded RNA-mediated TLR3 activation is enhanced by CD14.

Authors:  Hyun-Ku Lee; Stefan Dunzendorfer; Katrin Soldau; Peter S Tobias
Journal:  Immunity       Date:  2006-02       Impact factor: 31.745

Review 9.  Immunological and inflammatory functions of the interleukin-1 family.

Authors:  Charles A Dinarello
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

10.  Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy.

Authors:  Stacey L Demento; Stephanie C Eisenbarth; Harald G Foellmer; Craig Platt; Michael J Caplan; W Mark Saltzman; Ira Mellman; Michel Ledizet; Erol Fikrig; Richard A Flavell; Tarek M Fahmy
Journal:  Vaccine       Date:  2009-04-03       Impact factor: 3.641

View more
  5 in total

1.  Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity.

Authors:  Sarah N Mueller; Shaomin Tian; Joseph M DeSimone
Journal:  Mol Pharm       Date:  2015-04-08       Impact factor: 4.939

2.  Materials design at the interface of nanoparticles and innate immunity.

Authors:  Gregory Lee Szeto; Erin B Lavik
Journal:  J Mater Chem B       Date:  2016-01-29       Impact factor: 6.331

3.  Towards programming immune tolerance through geometric manipulation of phosphatidylserine.

Authors:  Reid A Roberts; Timothy K Eitas; James D Byrne; Brandon M Johnson; Patrick J Short; Karen P McKinnon; Shannon Reisdorf; J Christopher Luft; Joseph M DeSimone; Jenny P Ting
Journal:  Biomaterials       Date:  2015-08-20       Impact factor: 12.479

Review 4.  Clinical experiences with systemically administered siRNA-based therapeutics in cancer.

Authors:  Jonathan E Zuckerman; Mark E Davis
Journal:  Nat Rev Drug Discov       Date:  2015-11-16       Impact factor: 84.694

Review 5.  Power in Numbers: Harnessing Combinatorial and Integrated Screens to Advance Nanomedicine.

Authors:  Natalie Boehnke; Paula T Hammond
Journal:  JACS Au       Date:  2021-11-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.